These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 34425853)

  • 1. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tepotinib in Non-Small-Cell Lung Cancer with
    Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
    N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW; Chang JW; Wu CE
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
    Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
    Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
    Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ
    Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
    Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
    Roth KG; Mambetsariev I; Salgia R
    Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
    Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
    Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
    Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Fujino T; Suda K; Mitsudomi T
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of
    Subramanian J; Tawfik O
    Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.